| EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations MT McCabe, HM Ott, G Ganji, S Korenchuk, C Thompson, GS Van Aller, ... Nature 492 (7427), 108-112, 2012 | 1899 | 2012 |
| EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation W Béguelin, R Popovic, M Teater, Y Jiang, KL Bunting, M Rosen, H Shen, ... Cancer cell 23 (5), 677-692, 2013 | 910 | 2013 |
| The promise and peril of chemical probes CH Arrowsmith, JE Audia, C Austin, J Baell, J Bennett, J Blagg, C Bountra, ... Nature chemical biology 11 (8), 536-541, 2015 | 835 | 2015 |
| Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) MT McCabe, AP Graves, G Ganji, E Diaz, WS Halsey, Y Jiang, ... Proceedings of the National Academy of Sciences 109 (8), 2989-2994, 2012 | 539 | 2012 |
| A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models E Chan-Penebre, KG Kuplast, CR Majer, PA Boriack-Sjodin, TJ Wigle, ... Nature chemical biology 11 (6), 432-437, 2015 | 536 | 2015 |
| A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC HP Mohammad, KN Smitheman, CD Kamat, D Soong, KE Federowicz, ... Cancer cell 28 (1), 57-69, 2015 | 489 | 2015 |
| Identification of potent, selective, cell-active inhibitors of the histone lysine methyltransferase EZH2 SK Verma, X Tian, LV LaFrance, C Duquenne, DP Suarez, KA Newlander, ... ACS medicinal chemistry letters 3 (12), 1091-1096, 2012 | 405 | 2012 |
| SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer PK Mazur, N Reynoird, P Khatri, PWTC Jansen, AW Wilkinson, S Liu, ... Nature 510 (7504), 283-287, 2014 | 395 | 2014 |
| Assembly of the SIR complex and its regulation by O-acetyl-ADP-ribose, a product of NAD-dependent histone deacetylation GG Liou, JC Tanny, RG Kruger, T Walz, D Moazed Cell 121 (4), 515-527, 2005 | 329 | 2005 |
| Anti-tumor activity of the type I PRMT inhibitor, GSK3368715, synergizes with PRMT5 inhibition through MTAP loss A Fedoriw, SR Rajapurkar, S O'Brien, SV Gerhart, LH Mitchell, ND Adams, ... Cancer cell 36 (1), 100-114. e25, 2019 | 237 | 2019 |
| Vinyl sulfones: inhibitors of SrtA, a transpeptidase required for cell wall protein anchoring and virulence in Staphylococcus aureus BA Frankel, M Bentley, RG Kruger, DG McCafferty Journal of the American Chemical Society 126 (11), 3404-3405, 2004 | 224 | 2004 |
| Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation GS Van Aller, N Reynoird, O Barbash, M Huddleston, S Liu, AF Zmoos, ... Epigenetics 7 (4), 340-343, 2012 | 207 | 2012 |
| Analysis of the substrate specificity of the Staphylococcus aureus sortase transpeptidase SrtA RG Kruger, B Otvos, BA Frankel, M Bentley, P Dostal, DG McCafferty Biochemistry 43 (6), 1541-1551, 2004 | 188 | 2004 |
| Staphylococcus aureus sortase transpeptidase SrtA: insight into the kinetic mechanism and evidence for a reverse protonation catalytic mechanism BA Frankel, RG Kruger, DE Robinson, NL Kelleher, DG McCafferty Biochemistry 44 (33), 11188-11200, 2005 | 182 | 2005 |
| Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing SV Gerhart, WA Kellner, C Thompson, MB Pappalardi, XP Zhang, ... Scientific reports 8 (1), 9711, 2018 | 167 | 2018 |
| Chemistry and biology of the ramoplanin family of peptide antibiotics DG McCafferty, P Cudic, BA Frankel, S Barkallah, RG Kruger, W Li Peptide Science: Original Research on Biomolecules 66 (4), 261-284, 2002 | 152 | 2002 |
| Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia CC Bell, KA Fennell, YC Chan, F Rambow, MM Yeung, D Vassiliadis, ... Nature communications 10 (1), 2723, 2019 | 148 | 2019 |
| Distinct concentration-dependent effects of the polo-like kinase 1–specific inhibitor GSK461364A, including differential effect on apoptosis AG Gilmartin, MR Bleam, MC Richter, SG Erskine, RG Kruger, L Madden, ... Cancer research 69 (17), 6969-6977, 2009 | 136 | 2009 |
| Synergy and duality in peptide antibiotic mechanisms DG McCafferty, P Cudic, KY Michael, DC Behenna, R Kruger Current opinion in chemical biology 3 (6), 672-680, 1999 | 136 | 1999 |
| GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers P Sabbatini, S Korenchuk, JL Rowand, A Groy, Q Liu, D Leperi, C Atkins, ... Molecular cancer therapeutics 8 (10), 2811-2820, 2009 | 129 | 2009 |
